Budd-Chiari syndrome primary prevention: Difference between revisions
Mazia Fatima (talk | contribs) |
No edit summary |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Budd-Chiari syndrome}} | {{Budd-Chiari syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Mazia}} | ||
{{ | |||
==Overview== | ==Overview== | ||
Measures for the [[primary prevention]] of Budd-Chiari syndrome include effective management of predisposing conditions, [[chronic]] [[anticoagulation]] in patients with underlying [[Hypercoagulable state|hypercoagulable disorder]], treat [[patients]] with an underlying [[Myeloproliferative disease|myeloproliferative disorder]] with [[aspirin]] and [[hydroxyurea]] rather than [[anticoagulants]] such as [[warfarin]]. | |||
==Primary Prevention== | ==Primary Prevention== | ||
Measures for the primary prevention of Budd-Chiari syndrome include: | Measures for the [[primary prevention]] of Budd-Chiari syndrome include:<ref name="pmid26494427">{{cite journal |vauthors=Goel RM, Johnston EL, Patel KV, Wong T |title=Budd-Chiari syndrome: investigation, treatment and outcomes |journal=Postgrad Med J |volume=91 |issue=1082 |pages=692–7 |year=2015 |pmid=26494427 |doi=10.1136/postgradmedj-2015-133402 |url=}}</ref><ref name="pmid19652186">{{cite journal |vauthors=Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL |title=Etiology, management, and outcome of the Budd-Chiari syndrome |journal=Ann. Intern. Med. |volume=151 |issue=3 |pages=167–75 |year=2009 |pmid=19652186 |doi= |url=}}</ref> | ||
*Effective treatment of predisposing conditions | *Effective treatment of predisposing conditions | ||
*Chronic anticoagulation in patients with underlying hypercoagulable disorder | *[[Anticoagulation|Chronic anticoagulation]] in patients with underlying [[Hypercoagulable states|hypercoagulable disorder]] | ||
*Treat patients with an underlying [[Myeloproliferative disease|myeloproliferative disorder]] with [[aspirin]] and [[hydroxyurea]] rather than [[anticoagulants]] such as [[warfarin]]. | |||
==References== | ==References== | ||
Latest revision as of 21:36, 1 December 2017
|
Budd-Chiari syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Budd-Chiari syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Budd-Chiari syndrome primary prevention |
|
Risk calculators and risk factors for Budd-Chiari syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Measures for the primary prevention of Budd-Chiari syndrome include effective management of predisposing conditions, chronic anticoagulation in patients with underlying hypercoagulable disorder, treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin.
Primary Prevention
Measures for the primary prevention of Budd-Chiari syndrome include:[1][2]
- Effective treatment of predisposing conditions
- Chronic anticoagulation in patients with underlying hypercoagulable disorder
- Treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin.
References
- ↑ Goel RM, Johnston EL, Patel KV, Wong T (2015). "Budd-Chiari syndrome: investigation, treatment and outcomes". Postgrad Med J. 91 (1082): 692–7. doi:10.1136/postgradmedj-2015-133402. PMID 26494427.
- ↑ Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL (2009). "Etiology, management, and outcome of the Budd-Chiari syndrome". Ann. Intern. Med. 151 (3): 167–75. PMID 19652186.